Grant: Operating Grant
University of Toronto
$100,000.00
Pharmacological and biochemical basis of ligand-biased signalling at the Smoothened receptor.
FY 2015-16
Summary
Ligands for cell surface receptors are classically seen with activating or blocking properties for the signalling output these receptors control. In recent years, ligands have been characterized to have different intrinsic activities that are specific to the downstream signalling pathway regulated by the receptor under study. In this paradigm a ligand classified as neutral antagonist for one pathway can be a partial agonist at another pathway. Several ligands for the Hedgehog receptor Smoothened, which is a novel target in cancer, have recently been characterized to have such biased signalling properties. These findings have important implications for the identification of drugs with specific therapeutic properties and minimal side
effects. This proposal contributes to further understand the properties of the different ligands known to interact with Smoothened, identify new ligands with specific signalling properties and will provide more insights about the molecular mechanisms underlying Smoothened functions.
Department
Program
Operating Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
333012
Name
Angers Stephane
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
Pharmacological and biochemical basis of ligand-biased signalling at the Smoothened receptor.
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Gpcr; Hedgehog; Ligand Biased Signalling; Pharmacology; Structure Based Ligand Discovery; Synthetic Antibodies
Abstract
Ligands for cell surface receptors are classically seen with activating or blocking properties for the signalling output these receptors control. In recent years, ligands have been characterized to have different intrinsic activities that are specific to the downstream signalling pathway regulated by the receptor under study. In this paradigm a ligand classified as neutral antagonist for one pathway can be a partial agonist at another pathway. Several ligands for the Hedgehog receptor Smoothened, which is a novel target in cancer, have recently been characterized to have such biased signalling properties. These findings have important implications for the identification of drugs with specific therapeutic properties and minimal side
effects. This proposal contributes to further understand the properties of the different ligands known to interact with Smoothened, identify new ligands with specific signalling properties and will provide more insights about the molecular mechanisms underlying Smoothened functions.
Competitiondate
201505
Approvedterm2
1 yr 0 mth
Pinamesdelim
Angers, Stephane
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~